Disease Overview

Spontaneous remission

Not established

Best-intervention remission

—

Gap size

—

Primary barrier

—

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ATP4A 226 CHRM3 280 CLDN1 0 HRH2 218 IL8 152 PTGS2 299 TJP1 4 TRPV1 160

ATP4A

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
NIFEDIPINE	↑ activates	Mechanistic		DGIdb
EPIPREGNANOLONE SULPHATE	↑ activates	Mechanistic		DGIdb
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE	↓ inhibits	Mechanistic		DGIdb
PIOGLITAZONE HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
HALOTHANE	↓ inhibits	Mechanistic		DGIdb
NN-DIMETHYL-D-ERYTHROSPHINGOSINE	↑ activates	Mechanistic		DGIdb
NA+	↓ inhibits	Mechanistic		DGIdb
PREGNENOLONE SULPHATE	↑ activates	Mechanistic		DGIdb
(S)-LIQUIRITIGENIN	↓ inhibits	Mechanistic		DGIdb
ILAPRAZOLE	↓ inhibits	Mechanistic		DGIdb
CIM0216	↑ activates	Mechanistic		DGIdb
NARINGENIN	↓ inhibits	Mechanistic		DGIdb
MAPROTILINE	↓ inhibits	Mechanistic		DGIdb
TEGOPRAZAN	↓ inhibits	Mechanistic		DGIdb
LA3+	↓ inhibits	Mechanistic		DGIdb
ISOSAKURANETIN	↓ inhibits	Mechanistic		DGIdb
TROGLITAZONE	↓ inhibits	Mechanistic		DGIdb
SPHINGOSINE	↑ activates	Mechanistic		DGIdb
FEXUPRAZAN	↓ inhibits	Mechanistic		DGIdb
PENTAFLUORO-TRITYL CLOTRIMAZOLE ANALOGUE 29A	↑ activates	Mechanistic		DGIdb
GD3+	↓ inhibits	Mechanistic		DGIdb
ROSIGLITAZONE	↓ inhibits	Mechanistic		DGIdb
DIHYDROSPHINGOSINE	↑ activates	Mechanistic		DGIdb
PRIMIDONE	↓ inhibits	Mechanistic		DGIdb
2-APB	↓ inhibits	Mechanistic		DGIdb
OMEPRAZOLE MAGNESIUM	↓ inhibits	Mechanistic		DGIdb
CHLOROFORM	↓ inhibits	Mechanistic		DGIdb
MEFENAMIC ACID	↓ inhibits	Mechanistic		DGIdb
PANTOPRAZOLE SODIUM	↓ inhibits	Mechanistic		DGIdb
VONOPRAZAN FUMARATE	↓ inhibits	Mechanistic		DGIdb
RABEPRAZOLE	↓ inhibits	Mechanistic		DGIdb
OMEPRAZOLE	↓ inhibits	Mechanistic	3800.0 nM (IC50)	DGIdb
ESOMEPRAZOLE SODIUM	↓ inhibits	Mechanistic		DGIdb
LANSOPRAZOLE	↓ inhibits	Mechanistic	398.11 nM (IC50)	DGIdb
ESOMEPRAZOLE STRONTIUM	↓ inhibits	Mechanistic		DGIdb
DICLOFENAC SODIUM	↓ inhibits	Mechanistic		DGIdb
ABEPRAZAN	? unclear	Mechanistic		Open Targets
ESOMEPRAZOLE MAGNESIUM	? unclear	Mechanistic		Open Targets
RABEPRAZOLE SODIUM	? unclear	Mechanistic		Open Targets
DEXLANSOPRAZOLE	? unclear	Mechanistic		Open Targets

Showing top 40 of 226 agents ranked by evidence tier.

CHRM3

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
TARAFENACIN	? unclear	Mechanistic	DGIdb
METHIXENE	? unclear	Mechanistic	DGIdb
OXYBUTYNIN	↓ inhibits	Mechanistic	DGIdb
CEVIMELINE HYDROCHLORIDE	↑ activates	Mechanistic	DGIdb
ZAMIFENACIN	? unclear	Mechanistic	DGIdb
IMIDAFENACIN	↓ inhibits	Mechanistic	DGIdb
TIOTROPIUM	? unclear	Mechanistic	DGIdb
BENZQUINAMIDE	? unclear	Mechanistic	DGIdb
TOLTERODINE	↓ inhibits	Mechanistic	DGIdb
OCTOTROPINE METHYLBROMIDE	↓ inhibits	Mechanistic	DGIdb
SOLIFENACIN	? unclear	Mechanistic	DGIdb
DOXEPIN HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1084941	? unclear	Mechanistic	DGIdb
IPRATROPIUM CATION	↓ inhibits	Mechanistic	DGIdb
PROMAZINE	? unclear	Mechanistic	DGIdb
CLIDINIUM	↓ inhibits	Mechanistic	DGIdb
BATEFENTEROL	↓ inhibits	Mechanistic	DGIdb
BETHANECHOL CHLORIDE	↑ activates	Mechanistic	DGIdb
OLANZAPINE	? unclear	Mechanistic	DGIdb
OXYPHENCYCLIMINE	? unclear	Mechanistic	DGIdb
TRIDIHEXETHYL	? unclear	Mechanistic	DGIdb
ACETYLCHOLINE CHLORIDE	↑ activates	Mechanistic	DGIdb
METHACHOLINE CHLORIDE	↑ activates	Mechanistic	DGIdb
TRIDIHEXETHYL CHLORIDE	↓ inhibits	Mechanistic	DGIdb
CYCLOPENTOLATE HYDROCHLORIDE	↓ inhibits	Mechanistic	DGIdb
REVEFENACIN	↓ inhibits	Mechanistic	DGIdb
PIPERTRAMINE	? unclear	Mechanistic	DGIdb
FESOTERODINE	↓ inhibits	Mechanistic	DGIdb
CCG-50014	? unclear	Mechanistic	DGIdb
ATROPINE SULFATE	↓ inhibits	Mechanistic	DGIdb
PROMETHAZINE HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
ACLIDINIUM BROMIDE	↓ inhibits	Mechanistic	DGIdb
TROPICAMIDE	↓ inhibits	Mechanistic	DGIdb
DAROTROPIUM BROMIDE	↓ inhibits	Mechanistic	DGIdb
ACECLIDINE	? unclear	Mechanistic	DGIdb
SOLIFENACIN SUCCINATE	↓ inhibits	Mechanistic	DGIdb
DEXAMETHASONE	? unclear	Mechanistic	DGIdb
TIOTROPIUM BROMIDE	↓ inhibits	Mechanistic	DGIdb
TROSPIUM	↓ inhibits	Mechanistic	DGIdb
GLYCOPYRRONIUM	↓ inhibits	Mechanistic	DGIdb

Showing top 40 of 280 agents ranked by evidence tier.

CLDN1

UniProt Ensembl DGIdb Open Targets

Pipeline results not yet available for this target. Run the pipeline to populate.

HRH2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
NIZATIDINE	↓ inhibits	Mechanistic		DGIdb
FAMOTIDINE	↓ inhibits	Mechanistic		DGIdb
RANITIDINE BISMUTH CITRATE	↓ inhibits	Mechanistic		DGIdb
BETAZOLE	? unclear	Mechanistic		DGIdb
MS31	↓ inhibits	Mechanistic		DGIdb
RANITIDINE HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
BETAZOLE HYDROCHLORIDE	↑ activates	Mechanistic		DGIdb
EPINASTINE	? unclear	Mechanistic		DGIdb
LAFUTIDINE	↓ inhibits	Mechanistic		DGIdb
HISTAMINE	? unclear	Mechanistic	463.0 nM (EC50)	DGIdb
TOLAZOLINE HYDROCHLORIDE	↑ activates	Mechanistic		DGIdb
CIMETIDINE HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
EBROTIDINE	↓ inhibits	Mechanistic		DGIdb
DOXEPIN HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
METHANTHELINE BROMIDE	↓ inhibits	Mechanistic		DGIdb
ASENAPINE	? unclear	Mechanistic		DGIdb
CIMETIDINE	↓ inhibits	Mechanistic		DGIdb
MS8535	↓ inhibits	Mechanistic		DGIdb
TOLAZOLINE	? unclear	Mechanistic		Open Targets
METHANTHELINE	? unclear	Mechanistic		Open Targets
RANITIDINE	? unclear	Mechanistic		Open Targets
VUF-5297	↑ activates	Mechanistic	696.0 nM (EC50)	ChEMBL
CHEMBL72424	↓ inhibits	Mechanistic	10000.0 nM (Ki)	ChEMBL
CHEMBL70603	↓ inhibits	Mechanistic	10000.0 nM (Ki)	ChEMBL
CHEMBL44220	↓ inhibits	Mechanistic	19952.62 nM (Ki)	ChEMBL
CHEMBL72571	↓ inhibits	Mechanistic	3981.07 nM (Ki)	ChEMBL
CHEMBL310087	↓ inhibits	Mechanistic	12589.25 nM (Ki)	ChEMBL
CHEMBL70811	↓ inhibits	Mechanistic	1584.89 nM (Ki)	ChEMBL
CHEMBL72372	↓ inhibits	Mechanistic	1584.89 nM (Ki)	ChEMBL
CHEMBL418470	↑ activates	Mechanistic	93.0 nM (EC50)	ChEMBL
CHEMBL308717	↓ inhibits	Mechanistic	5011.87 nM (Ki)	ChEMBL
BURIMAMIDE	↓ inhibits	Mechanistic	3981.07 nM (Ki)	ChEMBL
VUF-5296	↑ activates	Mechanistic	2500.0 nM (EC50)	ChEMBL
CHEMBL305929	↓ inhibits	Mechanistic	3162.28 nM (Ki)	ChEMBL
CHEMBL104994	↓ inhibits	Mechanistic	22000.0 nM (Ki)	ChEMBL
CHEMBL107293	↓ inhibits	Mechanistic	380.0 nM (Ki)	ChEMBL
CHEMBL102840	↓ inhibits	Mechanistic	2300.0 nM (Ki)	ChEMBL
CHEMBL104808	↓ inhibits	Mechanistic	500.0 nM (Ki)	ChEMBL
CHEMBL105071	↓ inhibits	Mechanistic	730.0 nM (Ki)	ChEMBL
CHEMBL101634	↓ inhibits	Mechanistic	6200.0 nM (Ki)	ChEMBL

Showing top 40 of 218 agents ranked by evidence tier.

IL8

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
VITAMIN A	? unclear	Mechanistic	DGIdb
FENTANYL CITRATE	? unclear	Mechanistic	DGIdb
ALPRAZOLAM	? unclear	Mechanistic	DGIdb
FENRETINIDE	? unclear	Mechanistic	DGIdb
RIBAVIRIN	? unclear	Mechanistic	DGIdb
RECOMBINANT INTERLEUKIN-1	? unclear	Mechanistic	DGIdb
CIDOFOVIR ANHYDROUS	? unclear	Mechanistic	DGIdb
DIPYRIDAMOLE	? unclear	Mechanistic	DGIdb
TROGLITAZONE	? unclear	Mechanistic	DGIdb
LANSOPRAZOLE	? unclear	Mechanistic	DGIdb
IONOMYCIN	? unclear	Mechanistic	DGIdb
E319	? unclear	Mechanistic	DGIdb
CEFTRIAXONE	? unclear	Mechanistic	DGIdb
CHLORDANE	? unclear	Mechanistic	DGIdb
FOSCARNET	? unclear	Mechanistic	DGIdb
ADAKITUG	↓ inhibits	Mechanistic	DGIdb
DANAZOL	? unclear	Mechanistic	DGIdb
D-ALPHA-TOCOPHEROL ACETATE	? unclear	Mechanistic	DGIdb
DICYCLOHEXYLCARBODIIMIDE	? unclear	Mechanistic	DGIdb
RO 31-8220	? unclear	Mechanistic	DGIdb
BEVACIZUMAB	? unclear	Mechanistic	DGIdb
BROXURIDINE	? unclear	Mechanistic	DGIdb
TRETINOIN	? unclear	Mechanistic	DGIdb
ALL-TRANS-RETINAL	? unclear	Mechanistic	DGIdb
METHIMAZOLE	? unclear	Mechanistic	DGIdb
DEOXYSPERGUALIN	? unclear	Mechanistic	DGIdb
PAZOPANIB	? unclear	Mechanistic	DGIdb
OMEPRAZOLE	? unclear	Mechanistic	DGIdb
ALPHA-TOCOPHEROL ACETATE	? unclear	Mechanistic	DGIdb
MEDROXYPROGESTERONE ACETATE	? unclear	Mechanistic	DGIdb
ASPIRIN	? unclear	Mechanistic	DGIdb
TETRADECANOYLPHORBOL ACETATE	? unclear	Mechanistic	DGIdb
PENTOXIFYLLINE	? unclear	Mechanistic	DGIdb
PYROGALLOL	? unclear	Mechanistic	DGIdb
KLEBSIELLA PNEUMONIAE GLYCOPROTEIN	? unclear	Mechanistic	DGIdb
ABX-IL8	↓ inhibits	Mechanistic	DGIdb
FLUOROURACIL	? unclear	Mechanistic	DGIdb
BIOFLAVONOID	? unclear	Mechanistic	DGIdb
LEFLUNOMIDE	? unclear	Mechanistic	DGIdb
QUESTIOMYCIN B	? unclear	Mechanistic	DGIdb

Showing top 40 of 152 agents ranked by evidence tier.

PTGS2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
CARPROFEN	↓ inhibits	Mechanistic	102.0 nM (IC50)	DGIdb
INDOMETHACIN SODIUM	↓ inhibits	Mechanistic		DGIdb
DARBUFELONE	? unclear	Mechanistic		DGIdb
MEFENAMIC ACID	↓ inhibits	Mechanistic		DGIdb
MECLOFENAMATE SODIUM	↓ inhibits	Mechanistic		DGIdb
DICLOFENAC SODIUM	↓ inhibits	Mechanistic		DGIdb
CAPECITABINE	? unclear	Mechanistic		DGIdb
PIRPROFEN	↓ inhibits	Mechanistic		DGIdb
ESFLURBIPROFEN	↓ inhibits	Mechanistic		DGIdb
SULFASALAZINE	↓ inhibits	Mechanistic		DGIdb
BROMFENAC	? unclear	Mechanistic		DGIdb
IBUPROFEN, SODIUM SALT	↓ inhibits	Mechanistic		DGIdb
ALOXIPRIN	↓ inhibits	Mechanistic		DGIdb
TENOXICAM	? unclear	Mechanistic		DGIdb
FLURBIPROFEN	↓ inhibits	Mechanistic		DGIdb
SALICYLIC ACID	? unclear	Mechanistic		DGIdb
ATENOLOL	? unclear	Mechanistic		DGIdb
DEXKETOPROFEN	↓ inhibits	Mechanistic		DGIdb
ETORICOXIB	↓ inhibits	Mechanistic		DGIdb
LUMIRACOXIB	↓ inhibits	Mechanistic		DGIdb
SUPROFEN	↓ inhibits	Mechanistic		DGIdb
NS-398	? unclear	Mechanistic		DGIdb
NABUMETONE	↓ inhibits	Mechanistic		DGIdb
URSOLIC ACID	? unclear	Mechanistic		DGIdb
IBUPROFEN LYSINE	↓ inhibits	Mechanistic		DGIdb
ACECLOFENAC	↓ inhibits	Mechanistic		DGIdb
IBUFENAC	↓ inhibits	Mechanistic		DGIdb
BALSALAZIDE	? unclear	Mechanistic		DGIdb
DIFLUNISAL	↓ inhibits	Mechanistic		DGIdb
BALSALAZIDE DISODIUM	↓ inhibits	Mechanistic		DGIdb
VACCINE	? unclear	Mechanistic		DGIdb
KETOROLAC TROMETHAMINE	↓ inhibits	Mechanistic		DGIdb
BENZYDAMINE HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
TIAPROFENIC ACID	? unclear	Mechanistic		DGIdb
RALOXIFENE HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
NAPROXCINOD	↓ inhibits	Mechanistic		DGIdb
IGURATIMOD	↓ inhibits	Mechanistic		DGIdb
ETODOLAC	↓ inhibits	Mechanistic		DGIdb
DICLOFENAC ETALHYALURONATE SODIUM	↓ inhibits	Mechanistic		DGIdb
ROFECOXIB	↓ inhibits	Mechanistic	530.0 nM (IC50)	DGIdb

Showing top 40 of 299 agents ranked by evidence tier.

TJP1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
DEXAMETHASONE	? unclear	Mechanistic	DGIdb
RISPERIDONE	? unclear	Mechanistic	DGIdb
DEHYDRATED ALCOHOL	? unclear	Mechanistic	DGIdb
GENISTEIN	? unclear	Mechanistic	DGIdb

TRPV1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
STREPTOZOCIN	? unclear	Mechanistic		DGIdb
BENZYL ISOTHIOCYANATE	? unclear	Mechanistic		DGIdb
ACETAMINOPHEN	↑ activates	Mechanistic		DGIdb
POLYGODIAL	? unclear	Mechanistic		DGIdb
PROPOFOL	? unclear	Mechanistic		DGIdb
SAF312	↓ inhibits	Mechanistic		DGIdb
GRC-15300	? unclear	Mechanistic		DGIdb
AZD1386	↓ inhibits	Mechanistic		DGIdb
TIVANISIRAN	↓ inhibits	Mechanistic		DGIdb
MAVATREP	↓ inhibits	Mechanistic		DGIdb
MR-1817	↓ inhibits	Mechanistic		DGIdb
FERRUGINENE B	? unclear	Mechanistic		DGIdb
CAPSAICIN	↑ activates	Mechanistic	19.95 nM (EC50)	DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN	? unclear	Mechanistic		DGIdb
PHENETHYLISOTHIOCYANATE	? unclear	Mechanistic		DGIdb
VOACANGINE	? unclear	Mechanistic		DGIdb
RESINIFERATOXIN	↑ activates	Mechanistic	23.1 nM (Ki)	DGIdb
DWP05195	↓ inhibits	Mechanistic		DGIdb
XEN-D0501	↓ inhibits	Mechanistic		DGIdb
PAC-14028	↓ inhibits	Mechanistic		DGIdb
SB-705498	↓ inhibits	Mechanistic		DGIdb
MASOPROCOL	? unclear	Mechanistic		DGIdb
ALLYL ISOTHIOCYANATE	? unclear	Mechanistic		DGIdb
NGD-8243	↓ inhibits	Mechanistic		DGIdb
GRC-6211	↓ inhibits	Mechanistic		DGIdb
RESERPINE	? unclear	Mechanistic		DGIdb
NABIXIMOLS	? unclear	Mechanistic		DGIdb
A425619	? unclear	Mechanistic		DGIdb
PHE377	↓ inhibits	Mechanistic		DGIdb
ANTISENSE OLIGONUCLEOTIDES	? unclear	Mechanistic		DGIdb
WORTMANNIN	? unclear	Mechanistic		DGIdb
JTS-653	↓ inhibits	Mechanistic		DGIdb
LEVODOPA	? unclear	Mechanistic		DGIdb
AMG517	↓ inhibits	Mechanistic		DGIdb
CAPSAZEPINE	? unclear	Mechanistic	120.0 nM (Ki)	DGIdb
ZUCAPSAICIN	↑ activates	Mechanistic		DGIdb
INDOMETHACIN	? unclear	Mechanistic		DGIdb
CHEMBL:CHEMBL191534	? unclear	Mechanistic		DGIdb
ABT-102	↓ inhibits	Mechanistic		DGIdb
ISOPROPYL ISOTHIOCYANATE	? unclear	Mechanistic		DGIdb

Showing top 40 of 160 agents ranked by evidence tier.

Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-02.

Evaluation of the Fundoplicature of the Excluded Stomach Post Omega Bypass Recruiting

NCT06621979 Phase: NA Started: 2025-11-24

The purpose of this study is to evaluate the efficacy of fundoplication with stomach excluded in the suppression of disabling gastroesophageal reflux requiring surgery in patients who have undergone one anastomosis gastric bypass, with complete objective evaluation of reflux.

An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients Recruiting

NCT07678177 Phase: N/A Started: 2023-03-07

This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole Completed

NCT05055128 Phase: PHASE2 Started: 2021-08-11

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment hea...

Redo Surgery or Transcatheter Valve-in-Valve for Mitral Bioprosthetic Dysfunction (SURViV) Completed

NCT04402931 Phase: NA Started: 2020-02-17

Transcatheter valve-in-valve implantation has emerged as a valid alternative to redo surgery for patients with surgical bioprosthetic dysfunction. Nowadays, transcatheter, transeptal mitral valve-in-valve replacement (TsMViV) has been adopted in many centers worldwide. Some studies report low rates ...

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia Recruiting

NCT06534359 Phase: NA Started: 2025-07-15

The goal of this clinical trial is to learn if transpyloric tube feeding (feeding directly into the small intestine) versus gastric tube feeding tolerably and effectively reduces gastroesophageal reflux in infants born premature who have been diagnosed with bronchopulmonary dysplasia. The main quest...

Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants Recruiting

NCT05777512 Phase: NA Started: 2024-04-26

The purpose of this study is to determine if postpyloric feedings effectively improve objective measures of pulmonary health in preterm infants with chronic lung disease when compared with nasogastric (NG) feedings. This research will (1) determine the optimal nutritional management to prevent a com...

Esophagogastric Junction Distensibility During Hiatal Hernia Repair Active Not Recruiting

NCT04450628 Phase: NA Started: 2020-09-28

The investigators aim to ascertain the effects of hiatal hernia repair and fundoplication on the distensibility of the esophagogastric junction (EGJ) as measured by FLIP topography/impedance planimetry. The investigators also aim to assess for any correlation between values of EGJ distensibility and...

Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms Recruiting

NCT06613438 Phase: NA Started: 2024-09-15

The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD). The main questions this research aims to answer are: 1. Does the eGERD device reduce acidity in the esophagus? 2. Does the eGER...

Abbott Cephea Mitral Valve Disease Registry Recruiting

NCT07069673 Phase: N/A Started: 2025-08-13

The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of cor...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study Completed

NCT03105375 Phase: EARLY_PHASE1 Started: 2017-02-21

The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus Active Not Recruiting

NCT00431756 Phase: N/A Started: 2002-05-01

The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

The Detection of Barrett's Esophagus by Gastrointestinal Endoscopy Prevents Esophageal Carcinoma in Morbid Obese After Sleeve Gastrectomy Completed

NCT03596411 Phase: N/A Started: 2018-05-17

Severe Gastroesophageal reflux disease (GERD) leading to a chronic aggression of esophagus mucosa, called Barrett's esophagus is a main complication of Sleeve gastrectomy for morbid obesity. Barrett's esophagus is considered as a early stage of neoplastic transformation to adenocarcinoma. Since this...

Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare Recruiting

NCT07125521 Phase: NA Started: 2025-08-18

Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising po...

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy Active Not Recruiting

NCT03705416 Phase: N/A Started: 2019-03-30

GERD is common in the obese population. Bariatric procedures are the mainstay of therapy for these patients. Bariatric procedures can be surgical (Roux-en-Y gastric bypass and Vertical sleeve gastrectomy) or endoscopic (endoscopic sleeve gastroplasty). The rate of GERD after either treatment is unkn...

A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate Recruiting

NCT05469854 Phase: PHASE1 Started: 2022-07-13

This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linapra...

Agents Found By Disease-Level Search

Searched directly from “GERD (Gastroesophageal Reflux Disease)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

60 agents shown (approved or with trial evidence) — 54 not found by the gene-target search above.

Esomeprazole

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT04329000 NCT00317044 NCT00317044

pantoprazole

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00362609 NCT00307944 NCT01887743

Lansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01990339 NCT01135368

Vonoprazan

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05366738 NCT05366738

Dexlansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02616302 NCT00627016

Esomeprazole 40 mgNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04568772 NCT04329000

AZD3355NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00757419

EG Scan II (transnasal endoscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Standard EndoscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Lap Nissen fundoplication with division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Laparoscopic Nissen fundoplication without division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Standard dose (once daily) PPI plus low-dose antidepressantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

Double dose PPI plus evening placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

Rabeprazole , placebo, placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

gastroenteroanastomosis simultaneous to vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

NortriptylineNOT in gene-target list

Phase 2/3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01065649

Placebo armNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01065649

Thickened infant formulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02710955

Medtronic Intrepid™ TMVR TF SystemNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05496998

Dexrabeprazole 10 mg Enteric-Coated TabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02689999

Omeprazole

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00256737

High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06151067

AciphexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00204698

DIMAC02NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02789800

Atovaquone / Proguanil 250/100 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Tegoprazan 50 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Vonoprazan 20 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

YYD601 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Nexium 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

PlacebosNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Laparoscopic total left-sided surgical approachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07252115

Laparoscopic traditional bilateral approachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07252115

laparoscopic surgeryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01587859

Intravenous FamotidineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

Oral Maalox/ MylantaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

patients with GERD after LSGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05416645

Esophageal studiesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05180253

Endoscopic gastroplicationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00235677

Alginate-antacid groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

Non antacid alginate groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

Swallowable Sponge Cell Sampling DeviceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02890979

Laparoscopic fundoplication (surgery)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251927

CKD-381NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

NexiumNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

Tracheal LavageNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00865995

24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04454112

sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

sleeve gastrectomy with omentopexyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

One Anastomosis Gastric Bypass (OAGB)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04422405

ZegeridNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

LosecNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

AG1321001(drug)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00380315

IW-3718NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02030925

Matching PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02030925

commercially available lansoprazoleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03015610

matched placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03015610

SAPIEN Transcatheter Valve ImplantationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00676689

Cognitive Behavioral Therapy (CBT)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06939465

Lifestyle management (sham control)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06939465

GERD (Gastroesophageal Reflux Disease)

Disease Overview

ATP4A

CHRM3

CLDN1

HRH2

IL8

PTGS2

TJP1

TRPV1

Esomeprazole

pantoprazole

Lansoprazole

Vonoprazan

Dexlansoprazole

Esomeprazole 40 mgNOT in gene-target list

AZD3355NOT in gene-target list

EG Scan II (transnasal endoscopy)NOT in gene-target list

Standard EndoscopyNOT in gene-target list

Lap Nissen fundoplication with division of short gastric vesselsNOT in gene-target list

Laparoscopic Nissen fundoplication without division of short gastric vesselsNOT in gene-target list

Standard dose (once daily) PPI plus low-dose antidepressantNOT in gene-target list

Double dose PPI plus evening placeboNOT in gene-target list

Rabeprazole , placebo, placeboNOT in gene-target list

gastroenteroanastomosis simultaneous to vertical sleeve gastrectomyNOT in gene-target list

vertical sleeve gastrectomyNOT in gene-target list

NortriptylineNOT in gene-target list

Placebo armNOT in gene-target list

Thickened infant formulaNOT in gene-target list

Medtronic Intrepid™ TMVR TF SystemNOT in gene-target list

Dexrabeprazole 10 mg Enteric-Coated TabletsNOT in gene-target list

Omeprazole

High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testingNOT in gene-target list

AciphexNOT in gene-target list

DIMAC02NOT in gene-target list

Atovaquone / Proguanil 250/100 mgNOT in gene-target list

Tegoprazan 50 mgNOT in gene-target list

Vonoprazan 20 mgNOT in gene-target list

YYD601 40mgNOT in gene-target list

Nexium 40mgNOT in gene-target list

PlacebosNOT in gene-target list

Laparoscopic total left-sided surgical approachNOT in gene-target list

Laparoscopic traditional bilateral approachNOT in gene-target list

laparoscopic surgeryNOT in gene-target list

Intravenous FamotidineNOT in gene-target list

Oral Maalox/ MylantaNOT in gene-target list

patients with GERD after LSGNOT in gene-target list

Esophageal studiesNOT in gene-target list

Endoscopic gastroplicationNOT in gene-target list

Alginate-antacid groupNOT in gene-target list

Non antacid alginate groupNOT in gene-target list

Swallowable Sponge Cell Sampling DeviceNOT in gene-target list

Laparoscopic fundoplication (surgery)NOT in gene-target list

CKD-381NOT in gene-target list

NexiumNOT in gene-target list

Tracheal LavageNOT in gene-target list

24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).NOT in gene-target list

sleeve gastrectomyNOT in gene-target list

sleeve gastrectomy with omentopexyNOT in gene-target list

One Anastomosis Gastric Bypass (OAGB)NOT in gene-target list

ZegeridNOT in gene-target list

LosecNOT in gene-target list

AG1321001(drug)NOT in gene-target list

IW-3718NOT in gene-target list

Matching PlaceboNOT in gene-target list

commercially available lansoprazoleNOT in gene-target list

matched placeboNOT in gene-target list

SAPIEN Transcatheter Valve ImplantationNOT in gene-target list

Cognitive Behavioral Therapy (CBT)NOT in gene-target list

Lifestyle management (sham control)NOT in gene-target list

Part of the Open Source Medicine Foundation Network